Mangrove Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-12,517
Closed -$303K – 442
2026
Q2
$303K Sell
12,517
-1,191
-9% -$22.5K 0.02% 275
2026
Q1
$225K Buy
+13,708
New +$262K 0.02% 323

Other funds holding GLUE

Mangrove Partners's GLUE Position: Q3 2026 in Review

Mangrove Partners sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 12,517 shares — an estimated $303K sold.

Mangrove Partners first reported a position in GLUE in Q1 2026 and held it in 2 quarters. The position peaked at $303K in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Mangrove Partners reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Mangrove Partners sold 12,517 Monte Rosa Therapeutics shares in Q3 2026, an estimated $303K.
  • Mangrove Partners first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 2 quarters.
  • Mangrove Partners's Monte Rosa Therapeutics position peaked at $303K in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Mangrove Partners's 13F filing for Q3 2026, filed 16 Nov 2026.